Form 4 for HCAT Health Catalyst, Inc.
Accepted 2021-10-05 00:00:00 ET · period of report 2021-10-01 · accession 0001562180-21-006325 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2021-10-05 | 2021-10-01 | HCAT | Llewelyn Linda | CHRO | S - Sale+OE | $49.46 | -3,259 | 34.5K | -9% | -$161.2K |
| DM | 2021-10-05 | 2021-10-01 | HCAT | Llewelyn Linda | CHRO | M - OptEx | $11.48 | +3,150 | 36.9K | +9% | +$36.2K |
| DM | 2021-10-05 | 2021-10-01 | HCAT | Llewelyn Linda | CHRO | M - OptEx | $0.00 | -3,150 | 26.8K | -11% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2021-10-01 | S | D | 1,059 | $50.01 | 36,748 | D | — | — | |
| 2 | Common | Common Stock | 2021-10-01 | S | D | 2,200 | $49.20 | 34,548 | D | — | — | (F2) Represents the weighted average sale price of the shares sold ranging from $48.76 to $49.69 per share, inclusive. The Reporting Person will provide, upon request by the Issuer, a security holder of the Issuer, or the staff of the Securities and Exchange Commission, full information regarding the number of shares sold at each separate price within the range set forth in this Footnote. |
| 3 | Common | Common Stock | 2021-10-01 | M | A | 950 | $10.80 | 37,807 | D | — | — | |
| 4 | Common | Common Stock | 2021-10-01 | M | A | 2,200 | $11.78 | 36,857 | D | — | — | |
| 5 | Derivative | Stock Option (Right to Buy) | 2021-10-01 | M | D | 2,200 | $0.00 | 8,054 | D | $11.78 · — to 2028-01-24 | 2,200 Common Stock | (F3) 25% of the 17,954 shares underlying the options vested in an annual installment on January 24, 2019 and the remaining balance vested or will vest in equal monthly installments until the option vests in full on January 24, 2022. |
| 6 | Derivative | Stock Option (Right to Buy) | 2021-10-01 | M | D | 950 | $0.00 | 26,798 | D | $10.80 · — to 2028-09-27 | 950 Common Stock | (F4) 25% of the 59,351 shares underlying the options vested in an annual installment on September 25, 2019 and the remaining balance vested or will vest in equal monthly installments until the option vests in full on September 25, 2022. |